1-s2.0-088539249500087F-main.pdf
| Assessment Criterion | AI Analysis | AI Judgment | Issues |
|---|---|---|---|
|
S1: How representative was the exposed cohort?
cs_s1
|
Raw response parsing failed. Original content: {
"judgment": "no star awarded",
"scoring_rationale": "The exposed cohort consists of patients with neuropathic pain who underwent long-term intraspinal opioid infusion. The document describes a '...
|
no | |
|
S2: How was the non-exposed cohort selected?
cs_s2
|
The document describes a single cohort of patients with neuropathic pain who all received intraspinal opioid infusions. There is no mention of a separate non-exposed cohort, nor any description of how such a cohort would be selected. The study is a single-arm case series, not a cohort study with an unexposed comparison group. Therefore, the criterion for selection of the non-exposed cohort cannot be assessed, and no star is awarded.
|
no star awarded | |
|
S3: How was exposure ascertained?
cs_s3
|
Raw response parsing failed. Original content: {
"judgment": "star awarded",
"scoring_rationale": "The exposure (intraspinal opioid infusion) was ascertained through secure medical records and clinical procedures, including a multidisciplinary...
|
no | |
|
S4: Was the outcome of interest not present at the start of the study?
cs_s4
|
The document does not explicitly state that the outcome of interest (neuropathic pain) was absent at the start of the study. The study enrolls patients with existing neuropathic pain, and the outcome assessed is pain relief or failure of long-term pain relief, not the development of a new outcome. Since the criterion requires confirmation that the outcome was not present at baseline, and the text indicates all patients had neuropathic pain at enrollment, no star is awarded.
|
no star awarded | |
|
C1: Were the cohorts comparable on the basis of design or analysis, controlling for confounders?
cs_c1
|
Raw response parsing failed. Original content: {
"judgment": "no star awarded",
"scoring_rationale": "The document does not describe any comparison between cohorts or control for confounders. The study is a single-group prospective case series...
|
no | |
|
O1: How was the outcome assessed?
cs_o1
|
Raw response parsing failed. Original content: {
"judgment": "star awarded",
"scoring_rationale": "The outcome assessment was conducted by a disinterested third party who was independent and not involved in patient care, which meets the NOS cr...
|
no | |
|
O2: Was the follow-up long enough for outcomes to occur?
cs_o2
|
The follow-up duration is explicitly stated and sufficient for the outcome of interest (long-term pain relief). The mean follow-up time for successful patients is 2.4 ± 0.3 years (range 0.8–4.7 years), and for those with good outcome ratings, follow-up was significantly longer at 3.6 ± 0.4 years. The study also reports that most failures occurred within the first 3 years, and the Kaplan-Meier analysis shows follow-up extending beyond 3 years for successful patients. This duration is adequate to assess the chronic outcome of neuropathic pain relief.
|
star awarded | |
|
O3: Was the follow-up adequate (i.e., completeness)?
cs_o3
|
The document explicitly states that no patients were lost to follow-up, which constitutes complete follow-up and meets the NOS criterion for adequacy of follow-up. The statement is unambiguous and directly addresses the completeness of follow-up.
|
star awarded |